GAGandarvakottai Senthilkumar Arumugam

Gandarvakottai Senthilkumar Arumugam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gandarvakottai Senthilkumar Arumugam has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    “Synergistic anticancer effect of combined use of (plumbagin, cis-Isoshinanolone, 3’-O-β-glucopyranosyl plumbagic acid) isolated from Plumbago zeylanica , induces cell death through apoptosis in human HepG2 cancer cells”

    by Mohana Thiruchenduran, Navin Alukkathara Vijayan, Sathyanarayana N. Gummadi, Gandarvakottai Senthilkumar Arumugam, Sivasitamparam Niranjali Devaraj

    Plumbago zeylanica L., a traditional medicinal plant, has shown remarkable anti-cancer properties, making it imperative to delve into its chemical composition and biological effects. Fractions extracted from the roots of P. zeylanica exhibited cytotoxic activity, prompting further investigation through bioassay-guided fractionation and mass-directed isolation. This led to the discovery of three compounds: plumbagin (1), cis -Isoshinonolone (2), and 3’-O-β-glucopyranosyl plumbagic acid (3). The chemical structures of these compounds were elucidated through the analysis of 1D/2D NMR and MS data. Subsequent evaluation of compounds 1-3 for cytotoxic activity against human hepatoma cancer cells (HepG2) revealed potent effects, with all three compounds demonstrating IC 50 values of < 0.5 µM. The combined action of these bioactive compounds in P. zeylanic a was found to possess effective anti-cancer properties, exhibiting superior cytotoxic activity compared to individual compounds. Specifically, compound 3 emerged as the most potent natural product in the series, displaying an IC 50 value of 0.1 µM against the HepG2 cell line. In conclusion, compounds 1, 2 , and 3 from P. zeylanica showcase significant in vitro cytotoxic activity against HepG2 cells, underscoring their potential as promising candidates for further anti-cancer research and development.

  • Thermal and mechanical properties of high-performance polyester nanobiocomposites reinforced with pre-treated sunn hemp fiber for automotive applications

    by Gandarvakottai Senthilkumar Arumugam, Chinnappa Arumugam, Kannan Damodharan, R. Sathish Kumar, Sathyanarayana N. Gummadi, Sarojadevi Muthusamy


  • Open Access

    Discovery of a novel antibiotic, Transitmycin, from Streptomyces sp unveils highly efficient activities against tuberculosis and human immunodeficiency virus

    by Vanaja Kumar, Balagurunathan Ramasamy, Mukesh Doble, Radhakrishnan Manikkam, Luke Elizabeth Hanna, Gandarvakottai Senthilkumar Arumugam, Kannan Damodharan, Suresh Ganesan, Azger Dusthakeer, Precilla Lucia, et al.

    HIV is identified as a factor that aggravates tuberculosis disease pathogenesis and its progression to latent TB. While, TB is declared as one of the major causes for AIDS-associated mortality. So there is a dire need for new drugs to combat such ailments that have a synergistic interaction.This has led us to study a novel antibiotic purified from a marine Streptomyces sp isolated from the coral reef ecosystem of South Indian coast. Streptomyces sp. R2 (MTCC 5597; DSM 26035)., isolated from the marine water was grown on agar plates and the crude yellowish orange pigment secreted was extracted using various solvents. The antibiotic, named as Transitmycin, was purified and tested against M. tuberculosis, drug resistant strains, and M. tuberculosis biofilm. The compound was also tested against HIV-1 viruses belonging to six subtypes. Several characterisation tools were used to elucidate the structure of this novel antibiotic. Transitmycin was derivitaised to elucidate the absolute configurations of the amino acids present in it. Tr, unlike actinomycin D, has L-valine in both the rings instead of D-valine (found in the latter). Also, one of the proline in Tr is in D–configuration while it is in L configuration in actinomycin D suggesting that ours is a novel compound and is not reported so far. It exhibits dual activities against the standard H37Rv, 49 drug sensitive clinical isolates, and MtB biofilm as well as standard and 20 clinical isolates of HIV. This is the first paper that reports the isolation of a new antibiotic from marine actinobacteria exhibiting unusual anti-TB and HIV activities which could be exploited further as a lead molecule in the quest for the design of drug with dual activities. Highlights: A novel antibiotic was purified from a marine Streptomyces sp isolated from the coral reef of S. India Presence of L-valine, not observed in actinomycin D, and one of the proline in D configuration suggest that it is a novel structure not reported before It exhibits activity against standard MtB strain as well as clinical isolates and drug resistance ones It exhibits anti-HIV activity against several clinical isolates

  • Open Access

    Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity

    by Gandarvakottai Senthilkumar Arumugam, Kannan Damodharan, Mukesh Doble, Sathiah Thennarasu

    A virus enters a living organism and recruits host metabolism to reproduce its own genome and proteins. The viral infections are intricate and cannot be completely removed through existing antiviral drugs. For example, the herpes, influenza, hepatitis and human immunodeficiency viruses are a few dreadful ones amongst them. Significant studies are needed to understand the viral entry and their growth in host cells to design effective antivirals. This review emphasizes the range of therapeutical antiviral drugs, inhibitors along with vaccines to fight against viral pathogens, especially for combating COVID-19. Moreover, we have provided the basic and in depth information about viral targets, drugs availability, their mechanisms of action, method of prevention of viral diseases and highlighted the significances of anticoagulants, convalescent plasma for COVID-19 treatment, scientific details of airborne transmission, characteristics of antiviral drug delivery using nanoparticles/carriers, nanoemulsions, nanogels, metal based nanoparticles, alike the future nanosystems through nanobubbles, nanofibers, nanodiamonds, nanotraps, nanorobots and eventually, the therapeutic applications of micro- and nanoparticulates, current status for clinical development against COVID-19 together with environmental implications of antivirals, gene therapy etc., which may be useful for repurposing and designing of novel antiviral drugs against various dreadful diseases, especially the SARS-CoV-2 and other associated variants.


  • Open Access

    Potential of Terminalia Arjuna as a Promising PhytoremedyAgainst COVID-19: DPPH Scavenging, Catalase Inhibition and Molecular Docking Studies

    by Senthilkumar Arumugam, Swati Sucharita Dash, Kartik Mitra, Mukesh Doble, Sathyanarayana N.Gummadi

    Stem and bark of the tree Terminalia arjuna Wight &Arn. (Combretaceae) has been documented to exhibit therapeutic properties like cardiotonic, anticancer, antiviral, antibacterial, antifungal, hypocholsteremic, hypolipidemic and anti-coagulant. In previous studies, ethanolic extract of T.arjunabark effectively inhibited catalase activity along with demonstration of DPPH radical scavenging activity. Further,four known oleananetriterpenoids type compounds viz., oleanolic acid, arjunolic acid, arjunolitin, arjunetin were isolated from ethaolic bark extract and the structures of which were elucidated using 1 H, 13C NMR, HR-ESIMS, IR and compared with literature data. Of the various compounds, Arjunetin showed significant inhibition of catalase activity as compared to the other compounds and most probably conferring antibacterial and antiviral property of the extract. In the present study, considering the currently on going viral pandemic of SARS-CoV-2 and the need for an effective antiviral agent, T.arjuna with its cardioprotective ability and inhibitory action against catalase presents to be a promising candidate against the virus. Molecular docking studies showed that arjunetin binds to protease of SARS-CoV-2 (3CL, PL andRdRP) and had higher binder energy values (3CL, -8.4 kcal/mol; PL, -7.6 kcal/mol and RdRP, -8.1 kcal/mol as compared with FDA approved protease inhibitor drugs lopinavir (3CL, -7.2 kcal/mole and PL -7.7 kcal/mole) and Remdesivir (RdRP -7.6 kcal/ mole). We conclude that there is profound evidence of arjunetin as a potential protease inhibitor of SARS-CoV-2 which is comparable to FDA approved antivirals Lopinavir and Remdesivir and can serve as a candidate for drug development against SARS-CoV-2.